NetworkNewsBreaks – MediWound Ltd. (NASDAQ: MDWD) Still Inching Higher on Positive NexoBrid Results
Shares of MediWound (NASDAQ: MDWD) are ticking higher a day after the company reported positive results from its phase 2 study evaluating the safety, pharmacokinetics (transcutaneous absorption) and efficacy of NexoBrid in hospitalized children and adults with severe thermal burns. As a topically administered eschar removal agent, NexoBrid provides a much needed alternative to surgical excision. Surgery of large surfaces of eschar is often limited by the availability of the extensive donor site required. Additionally, surgical excision results in significant surgical burden on these very severe patients including immense blood loss. The phase 2 study included 36 patients with severe…







